A biosimilar version of the rheumatoid arthritis drug Remicade will soon be available.
Pfizer Inc said on Monday it will begin shipping its biosimilar version of Johnson & Johnson’s blockbuster rheumatoid arthritis drug Remicade in late November at a 15 percent discount to current wholesale prices.
The Pfizer drug, to be sold under the name Inflectra, is already available in Europe and other overseas markets and would be the second biosimilar medicine available in the United States.
As it is not possible to produce exact copies of biotech drugs made from living cells, the cheaper versions – referred to as biosimilars rather than generics – are intended to provide cost savings compared with pricey biologic medicines.
Read Full Article: Pfizer to start shipping biosimilar version of Remicade – Business Insider
|Read Full Article: Pfizer to start shipping biosimilar version of Remicade – Business Insider|